Eyenovia, Inc. Common Stock, also called Eyenovia, is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. Read More The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.